SA
ABBV icon

Skyline Advisors’s AbbVie ABBV Stock Holding History

Skyline Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,125
Closed -$209K – 97
2025
Q2 		$209K Buy
+1,125
New +$209K 0.08% 94
2024
Q4 		– Sell
-1,346
Closed -$266K – 95
2024
Q3 		$266K Sell
1,346
-108
-7% -$20.2K 0.11% 75
2024
Q2 		$249K Sell
1,454
-33
-2% -$5.47K 0.11% 70
2024
Q1 		$271K Buy
1,487
+4
+0.3% +$689 0.12% 69
2023
Q4 		$230K Buy
+1,483
New +$216K 0.11% 70

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Skyline Advisors's ABBV Position: Q3 2025 in Review

Skyline Advisors sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 1,125 shares — an estimated $209K sold.

Skyline Advisors first reported a position in ABBV in Q4 2023 and held it in 5 quarters. The position peaked at $271K in Q1 2024. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Skyline Advisors reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
  • Skyline Advisors sold 1,125 AbbVie shares in Q3 2025, an estimated $209K.
  • Skyline Advisors first reported a position in AbbVie in Q4 2023 and held it in 5 quarters.
  • Skyline Advisors's AbbVie position peaked at $271K in Q1 2024.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Skyline Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.